» Articles » PMID: 38240343

Identifying Determinants of Adherence to Adjuvant Endocrine Therapy Following Breast Cancer: A Systematic Review of Reviews

Abstract

Background: In oestrogen-receptor positive breast cancer, daily oral adjuvant endocrine therapy (ET) for at least 5 years significantly reduces risks of recurrence and breast cancer-specific mortality. However, many women are poorly adherent to ET. Development of effective adherence support requires comprehensive understanding of influences on adherence. We undertook an umbrella review to identify determinants of ET adherence.

Methods: We searched PubMed, Embase, CINAHL, PsycINFO, Cochrane and PROSPERO (inception to 08/2022) to identify systematic reviews on factors influencing ET adherence. Abstracted determinants were mapped to the World Health Organization's dimensions of adherence. Reviews were quality appraised and overlap assessed.

Results: Of 5732 citations screened, 17 reviews were eligible (9 quantitative primary studies; 4 qualitative primary studies; 4 qualitative or quantitative studies) including 215 primary papers. All five WHO dimensions influenced ET non-adherence: The most consistently identified non-adherence determinants were patient-related factors (e.g. lower perceived ET necessity, more treatment concerns, perceptions of ET 'cons' vs. 'pros'). Healthcare system/healthcare professional-related factors (e.g. perceived lower quality health professional interaction/relationship) were also important and, to a somewhat lesser extent, socio-economic factors (e.g. lower levels of social/economic/material support). Evidence was more mixed for medication-related and condition-related factors, but several may be relevant (e.g. experiencing side-effects, cost). Potentially modifiable factors are more influential than non-modifiable/fixed factors (e.g. patient characteristics).

Conclusions: The evidence-base on ET adherence determinants is extensive. Future empirical studies should focus on less well-researched areas and settings. The determinants themselves are numerous and complex in indicating that adherence support should be multifaceted, addressing multiple determinants.

Citing Articles

The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.

Neuner J, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V Breast Cancer Res Treat. 2024; 209(3):541-552.

PMID: 39592520 DOI: 10.1007/s10549-024-07513-5.


Clinical Pharmacist-Led Interventions for Improving Breast Cancer Management-A Scoping Review.

Staynova R, Gavazova E, Kafalova D Curr Oncol. 2024; 31(8):4178-4191.

PMID: 39195295 PMC: 11352950. DOI: 10.3390/curroncol31080312.


Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery.

Johnsson A, von Wachenfeldt A Cancer Rep (Hoboken). 2024; 7(8):e2160.

PMID: 39158164 PMC: 11331500. DOI: 10.1002/cnr2.2160.


Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.

Lee A, Lyons A, Makris V, Kamaraju S, Stolley M, Neuner J Support Care Cancer. 2024; 32(4):265.

PMID: 38565669 PMC: 11698022. DOI: 10.1007/s00520-024-08463-w.


Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews.

Todd A, Waldron C, McGeagh L, Norris R, Bolnykh I, Stewart S Cancer Med. 2024; 13(3):e6937.

PMID: 38240343 PMC: 10905548. DOI: 10.1002/cam4.6937.

References
1.
Sawesi S, Carpenter J, Jones J . Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review. Clin J Oncol Nurs. 2014; 18(3):E50-7. DOI: 10.1188/14.CJON.E50-E57. View

2.
Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

3.
Hadji P . Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2009; 73(2):156-66. DOI: 10.1016/j.critrevonc.2009.02.001. View

4.
Paranjpe R, John G, Trivedi M, Abughosh S . Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2018; 174(2):297-305. DOI: 10.1007/s10549-018-05073-z. View

5.
Xu H, Zhang X, Wang D, Xu L, Wang A . Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: A qualitative systematic review. J Adv Nurs. 2019; 76(2):445-458. DOI: 10.1111/jan.14253. View